455 related articles for article (PubMed ID: 18603570)
1. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours.
Pape UF; Berndt U; Müller-Nordhorn J; Böhmig M; Roll S; Koch M; Willich SN; Wiedenmann B
Endocr Relat Cancer; 2008 Dec; 15(4):1083-97. PubMed ID: 18603570
[TBL] [Abstract][Full Text] [Related]
2. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors.
Pape UF; Jann H; Müller-Nordhorn J; Bockelbrink A; Berndt U; Willich SN; Koch M; Röcken C; Rindi G; Wiedenmann B
Cancer; 2008 Jul; 113(2):256-65. PubMed ID: 18506737
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization.
Panzuto F; Nasoni S; Falconi M; Corleto VD; Capurso G; Cassetta S; Di Fonzo M; Tornatore V; Milione M; Angeletti S; Cattaruzza MS; Ziparo V; Bordi C; Pederzoli P; Delle Fave G
Endocr Relat Cancer; 2005 Dec; 12(4):1083-92. PubMed ID: 16322345
[TBL] [Abstract][Full Text] [Related]
4. Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors.
Strosberg J; Nasir A; Coppola D; Wick M; Kvols L
Hum Pathol; 2009 Sep; 40(9):1262-8. PubMed ID: 19368957
[TBL] [Abstract][Full Text] [Related]
5. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
6. Gastroenteropancreatic neuroendocrine tumors: incidence and treatment outcome in a single institution in Korea.
Lim T; Lee J; Kim JJ; Lee JK; Lee KT; Kim YH; Kim KW; Kim S; Sohn TS; Choi DW; Choi SH; Chun HK; Lee WY; Kim KM; Jang KT; Park YS
Asia Pac J Clin Oncol; 2011 Sep; 7(3):293-9. PubMed ID: 21884442
[TBL] [Abstract][Full Text] [Related]
7. [Clinicopathological features and multivariate analysis of prognostic factors for patients with gastroenteropancreatic neuroendocrine tumors].
Wang X; Song ZF; Yao WX; Pan CC; Xiang MF; Wang H
Zhonghua Yi Xue Za Zhi; 2013 May; 93(18):1411-4. PubMed ID: 24025507
[TBL] [Abstract][Full Text] [Related]
8. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters.
Niederle MB; Hackl M; Kaserer K; Niederle B
Endocr Relat Cancer; 2010 Dec; 17(4):909-18. PubMed ID: 20702725
[TBL] [Abstract][Full Text] [Related]
9. [Neuroendocrine tumors of the gastroenteropancreatic system--reevaluation using the Capella classification].
Brüwer M; Pahlov-Nejad T; Herbst H; Senninger N; Schürmann G
Zentralbl Chir; 2003 Aug; 128(8):656-62. PubMed ID: 12931261
[TBL] [Abstract][Full Text] [Related]
10. Surgical strategies and predictors of outcome for malignant neuroendocrine tumors of the pancreas.
Bahra M; Jacob D; Pascher A; Plockinger U; Kristiansen G; Neuhaus P; Langrehr JM
J Gastroenterol Hepatol; 2007 Jun; 22(6):930-5. PubMed ID: 17489964
[TBL] [Abstract][Full Text] [Related]
11. Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors.
Bilimoria KY; Bentrem DJ; Merkow RP; Tomlinson JS; Stewart AK; Ko CY; Talamonti MS
J Am Coll Surg; 2007 Oct; 205(4):558-63. PubMed ID: 17903729
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma.
Durante C; Boukheris H; Dromain C; Duvillard P; Leboulleux S; Elias D; de Baere T; Malka D; Lumbroso J; Guigay J; Schlumberger M; Ducreux M; Baudin E
Endocr Relat Cancer; 2009 Jun; 16(2):585-97. PubMed ID: 19240182
[TBL] [Abstract][Full Text] [Related]
13. The significance of CD44 expression in gastrointestinal neuroendocrine tumors.
Lai CH; Shan YS; Sy ED; Hsieh YH; Tsai HW; Lee JC; Lin PW
Hepatogastroenterology; 2005; 52(64):1071-6. PubMed ID: 16001632
[TBL] [Abstract][Full Text] [Related]
14. Clinical course of neuroendocrine tumors with different origins (the pancreas, gastrointestinal tract, and lung).
Kim SJ; Kim JW; Oh DY; Han SW; Lee SH; Kim DW; Im SA; Kim TY; Heo DS; Bang YJ
Am J Clin Oncol; 2012 Dec; 35(6):549-56. PubMed ID: 21659833
[TBL] [Abstract][Full Text] [Related]
15. The epidemiology of gastroenteropancreatic neuroendocrine tumors.
Lawrence B; Gustafsson BI; Chan A; Svejda B; Kidd M; Modlin IM
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):1-18, vii. PubMed ID: 21349409
[TBL] [Abstract][Full Text] [Related]
16. Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience.
Scigliano S; Lebtahi R; Maire F; Stievenart JL; Kianmanesh R; Sauvanet A; Vullierme MP; Couvelard A; Belghiti J; Ruszniewski P; Le Guludec D
Endocr Relat Cancer; 2009 Sep; 16(3):977-90. PubMed ID: 19470616
[TBL] [Abstract][Full Text] [Related]
17. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications.
Strosberg JR; Cheema A; Weber JM; Ghayouri M; Han G; Hodul PJ; Kvols LK
Ann Surg; 2012 Aug; 256(2):321-5. PubMed ID: 22415420
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE).
Martin-Perez E; Capdevila J; Castellano D; Jimenez-Fonseca P; Salazar R; Beguiristain-Gomez A; Alonso-Orduña V; Martinez Del Prado P; Villabona-Artero C; Diaz-Perez JA; Monleon A; Marazuela M; Pachon V; Sastre-Valera J; Sevilla I; Castaño A; Garcia-Carbonero R
Neuroendocrinology; 2013; 98(2):156-68. PubMed ID: 23988576
[TBL] [Abstract][Full Text] [Related]
19. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II-specific NE tumour types.
Oberg K; Astrup L; Eriksson B; Falkmer SE; Falkmer UG; Gustafsen J; Haglund C; Knigge U; Vatn MH; Välimäki M;
Acta Oncol; 2004; 43(7):626-36. PubMed ID: 15545183
[TBL] [Abstract][Full Text] [Related]
20. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients.
Bilimoria KY; Talamonti MS; Tomlinson JS; Stewart AK; Winchester DP; Ko CY; Bentrem DJ
Ann Surg; 2008 Mar; 247(3):490-500. PubMed ID: 18376195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
